CDMOs rush to expand capacity as GLP‑1 demand surges

GLP-1 drug demand is no longer just a commercial story for Novo Nordisk and Eli Lilly. It is now a manufacturing story for the contract development and manufacturing organizations that make peptides, fill injectable products and package devices at scale. Trade publications including World Pharma Today said this week that demand for metabolic therapies is driving facility upgrades, new equipment purchases and a scramble for outsourced production slots. The pressure point is capacity. World Pharma Today said pharmaceutical companies are turning to external manufacturers because internal networks cannot expand fast enough to match demand, and that CDMOs are adding cleanroom space, fill-finish lines and other specialized equipment to support GLP-1 production. ### Why are CDMOs suddenly central to the GLP-1 supply chain? GLP-1 medicines require more than a single production step. (worldpharmatoday.com) World Pharma Today said the manufacturing push spans peptide production, sterile processing, device-related work and other tightly scheduled operations, making outside partners a critical part of commercial supply plans. CordenPharma gave one of the clearest examples on July 16, 2024, when it said it would invest about 900 million euros over three years to expand large-scale GMP peptide manufacturing in the United States and Europe for the growing GLP-1 peptide agonist market. (worldpharmatoday.com) The company said the Colorado expansion was backed by multiple long-term manufacturing contracts totaling about 3 billion euros, with potential upside. ### What kind of capacity is being added? Large peptide capacity is one target, but not the only one. World Pharma Today said CDMOs are building new cleanroom environments and installing advanced fill-finish lines to support sterile, stable production for GLP-1 formulations. Resilience said in a company release carried by World Pharma Today that it is expanding clinical and commercial drug-product manufacturing capabilities and capacities, adding that its team already supports a leading pharmaceutical company with GLP-1 products. (cordenpharma.com) In a separate World Pharma Today item, Resilience and Eli Lilly were described as expanding their partnership with a $750 million investment in Ohio manufacturing operations. (worldpharmatoday.com) ### Why does licensed commercial manufacturing matter so much? Porton Advanced’s latest regulatory step shows where some CDMOs want to move next. Contract Pharma reported that Porton Advanced Solutions received a Drug Manufacturing License, Class C, from China’s regulator, allowing the company to extend services into commercialization rather than stopping at development support. That matters because commercial manufacturing contracts tend to run longer and tie customers more closely to a supplier’s validated network. (worldpharmatoday.com) World Pharma Today said drugmakers are competing for scarce global manufacturing resources and are prioritizing faster tech transfer and more secure outsourced capacity. ### Are partnerships replacing greenfield expansion? Partnerships are one faster route. (contractpharma.com) The Times of India reported that Gland Pharma and Neuland entered a long-term sterile API CDMO partnership, adding another example of companies using specialist networks rather than building every capability in-house. The same pattern appears across GLP-1 outsourcing, where trade coverage describes pharmaceutical companies assembling supply through multiple outside manufacturers. (worldpharmatoday.com) Neuland has also linked peptide demand directly to new investment. Contract Pharma reported this year that one of four planned modules at Neuland was the result of a $30 million investment, as the company navigated what it called an explosion in peptide popularity. ### What should readers watch next? The next concrete signals will come from plant openings, licensing milestones and contract announcements. (worldpharmatoday.com) CordenPharma said its 900 million euro peptide expansion will unfold over three years, Resilience and Lilly have tied new spending to Ohio manufacturing, and Porton Advanced now has a regulatory basis to add commercial work in China. (cordenpharma.com) (contractpharma.com)